AMCA
FATE icon

Arthur M. Cohen & Associates’s Fate Therapeutics FATE Stock Holding History

Arthur M. Cohen & Associates’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,206
Closed -$278K – 140
2021
Q2 		$278K Hold
3,206
– – 0.05% 128
2021
Q1 		$264K Hold
3,206
– – 0.06% 128
2020
Q4 		$292K Buy
+3,206
New +$199K 0.07% 125

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Arthur M. Cohen & Associates's FATE Position: Q3 2021 in Review

Arthur M. Cohen & Associates sold out of Fate Therapeutics (FATE) in Q3 2021, closing a stake of 3,206 shares — an estimated $278K sold.

Arthur M. Cohen & Associates first reported a position in FATE in Q4 2020 and held it in 3 quarters. The position peaked at $292K in Q4 2020. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

  • Arthur M. Cohen & Associates reported no remaining Fate Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Arthur M. Cohen & Associates sold 3,206 Fate Therapeutics shares in Q3 2021, an estimated $278K.
  • Arthur M. Cohen & Associates first reported a position in Fate Therapeutics in Q4 2020 and held it in 3 quarters.
  • Arthur M. Cohen & Associates's Fate Therapeutics position peaked at $292K in Q4 2020.
  • 265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on Arthur M. Cohen & Associates's 13F filing for Q3 2021, filed 8 Oct 2021.